Skip to content

Fundamental & clinical pharmacology

ISSN 1472-8206

3 papers in the library · 50 citations · publishing 1992-2026

Papers

Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice.

Fundamental & clinical pharmacology January 1, 1992 B Francés, R Gout, J Cros et al. 46 citations

In mice, a tremor-inducing dose of ibogaine did not relieve pain on its own but made morphine more effective at relieving pain. In morphine-dependent mice, ibogaine did not reduce withdrawal symptoms; instead, it increased the number of vertical jumps caused by naloxone, a drug that triggers withdrawal. This effect was specific to opioid withdrawal, as ibogaine did not alter jumping caused by a different drug. The results indicate that ibogaine modulates morphine's pain-relieving effects but does not lessen opioid withdrawal signs in mice, contrasting with reports of it alleviating opiate dependence in humans.

Detection of ketamine in the oral fluid of drivers in northeastern France during the years 2020-2023.

Fundamental & clinical pharmacology April 1, 2025 Laïyna Lilo Aouichi, Elise Pape, Jean-Yves Jouzeau et al. 4 citations

About 2.6% of drivers who tested positive for drugs in roadside checks in northeastern France over 32 months (2020–2023) had ketamine in their oral fluid. Among 88 ketamine-positive drivers, 80.7% were male, 95.4% used multiple drugs, and their average age was 27.5 years. Ketamine concentrations averaged 821 ng/mL when norketamine was also present and 7.8 ng/mL when it was absent. Roughly 26% of ketamine-positive drivers had oral fluid levels potentially linked to impaired driving. The authors suggest adding ketamine and norketamine to routine oral fluid drug testing for driving under the influence.

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental & clinical pharmacology July 1, 2026 Nina Abukahok, Steven Lawrence, Samrachana Adhikari et al.

In the New York metropolitan area, over a third of clinics advertising ketamine for psychiatric conditions offer it for at-home use, raising safety concerns. A 2025 systematic web search identified 233 clinics; 36.5% prescribed ketamine for at-home use, 51.5% listed a medical doctor, 42.9% advertised oral ketamine, and depression was the most common condition treated (94.0%). Clinics advertising oral ketamine were over four times more likely to offer at-home use, while those listing a medical doctor were about half as likely. The findings suggest a consumer-oriented advertising approach that may warrant monitoring and clearer guidance to mitigate safety risks.